Company intelligence / Profile preview

Hormos Medical

Turku, Varsinais-Suomi, Finland

Ownership: Private
Development stage: Other

Overview

Hormos Medical developed a platform for tissue-selective modulation of steroid hormone activity, advancing programs for endometriosis and male hypogonadism. The company’s lead asset, fispemifene, showed efficacy in early clinical studies. Its endometriosis program targeted the 17B-HSD1 enzyme and was in preclinical development at the time of asset transfer to Forendo Pharma. The company was acquired by QuatRx Pharmaceuticals; its core team later formed Forendo Pharma to continue development on these programs.

Therapeutic areas: Men's HealthEndocrinologyWomen's Health
Modalities: Small molecules (notably tissue-specific modulators of steroid hormones)
Industry: Biotech

Partnerships

No major pharma partnerships identified prior to acquisition; post-acquisition collaborations continued under Forendo Pharma with academic partners.

Beyond the preview

Go deeper on Hormos Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hormos Medical.